Study Drug Details
Parkinson’s disease is a brain disorder that progresses over time. It can cause shaking, stiff muscles and slow or unsteady movements. It can also affect sleep and memory.
New research shows that inflammation in the brain plays an important role in Parkinson’s disease. People with Parkinson’s disease often have high levels of inflammation in their brains and bodies. This inflammation can lead to damage associated with worsening of Parkinson’s symptoms and progression of Parkinson’s disease. In lab animals, some medicines that can effectively decrease inflammation have helped reduce this damage.
BHV-8000 is an investigational medicine being studied for Parkinson’s disease. It works to lower inflammation, which may impact the progression of Parkinson’s disease.
Study Details
SCREENING PHASE
There will be a Screening Phase lasting up to 8 weeks. Because of the procedures required, there could be multiple visits needed to complete all screening tests and procedures.
DOUBLE-BLIND STUDY PHASE
This phase is 48 weeks long with the Baseline Visit and 12 study visits.
DOUBLE-BLIND STUDY CONCLUSION
At the conclusion of the Double-blind phase, you may have an option to join the “Open-label” phase of the study, if you qualify and also agree to participate. This is an additional 48 weeks long .
FOLLOW-UP PHASE
This visit is scheduled 4 weeks after your last visit in the study.
There may be visits which the study doctor schedules, in addition to those above.